Evaluation of a Renin Inhibitor, Aliskiren, Compared to Enalapril, in C3 Glomerulopathy

NCT04183101 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

C3 Glomerulopathy
Membranoproliferative Glomerulonephritis
Complement Abnormality
Dense Deposit Disease
C3 Glomerulonephritis

Interventions

DRUG: Aliskiren
DRUG: Enalapril

Sponsor

Region Skane